Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies

Frontiers in Immunology

Immunology

Mona O. Mohsen¹  Anne-Cathrine S. Vogt¹  Pascal S. Krenger¹  Xinyue Chang¹  Monique Vogel¹  Martin F. Bachmann²  Lukas Jörg³  Byron Martina⁴  Andris Zeltins⁵ 

[1] Department of Rheumatology and Immunology, University Hospital, Bern, Switzerland;Department of BioMedical Research, University of Bern, Bern, Switzerland;Department of Rheumatology and Immunology, University Hospital, Bern, Switzerland;Department of BioMedical Research, University of Bern, Bern, Switzerland;Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, United Kingdom;Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland;Erasmus Medical Center, Department of Viroscience, Rotterdam, Netherlands;Artemis Bio-Support, Delft, Netherlands;Latvian Biomedical Research & Study Centre, Riga, Latvia;

关键词: SARS-CoV-2;    vaccine;    virus-like particles;    mRNA;    COVID-19;   

DOI  :  10.3389/fimmu.2022.864718

 received in 2022-01-28, accepted in 2022-05-05,  发布年份 2022

来源: Frontiers

【 摘 要 】

mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody responses for the control of continuously emerging SARS-CoV-2 variants of concern (VoCs) and to overcome other obstacles such as supply shortage, costs and reduced safety issues or inadequatly induced immune-responses. In this study, we investigated the antibody responses induced by heterologous prime-boost with vaccines based on mRNA and virus-like particles (VLPs). The VLP-based mCuMVTT-RBM vaccine candidate and the approved mRNA-1273 vaccine were used for this purpose. We find that homologous prime boost regimens with either mRNA or VLP induced high levels of high avidity antibodies. Optimal antibody responses were, however, induced by heterologous regimens both for priming with mRNA and boosting with VLP and vice versa, priming with VLP and boosting with mRNA. Thus, heterologous prime boost strategies may be able to optimize efficacy and economics of novel vaccine strategies.

【 授权许可】

Unknown   
Copyright © 2022 Vogt, Jörg, Martina, Krenger, Chang, Zeltins, Vogel, Mohsen and Bachmann